Activation of the prostaglandin D2 receptor (PTGDR) may contribute to pulmonary vasodilation, bronchoconstriction, recruitment of eosinophils, basophils and T-lymphocytes, and enhanced synthesis of leukotriene C4. We investigated whether polymorphisms of the leukotriene C4 synthase (LTC4S) À444A/C and PTGDR À441T/C were associated with clinical phenotypes and responsiveness to leukotriene receptor antagonist (LTRA) in Korean asthmatic children. We enrolled 270 normal and 870 asthmatic children. We prescribed montelukast (5 mg per day) to 100 of asthmatic children, and analyzed the responsiveness to LTRA by exercise challenge tests. Polymorphisms were genotyped by PCR-restriction fragment length polymorphism. As the number of minor alleles of the PTGDR À441T/C and LTC4S À444A/C polymorphisms increased, the log total eosinophil counts increased in atopic asthmatic children (P-value¼0.03). We found a significant association between responsiveness to montelukast and the PTGDR polymorphism (P-value¼0.038). However, the LTC4S À444A/C and PTGDR À441T/C were not associated with the susceptibility for asthma (LTC4S, AA versus AC+CC, adjusted odds ratio of 0.98 (95% confidence interval, 0.73-1.31); PTGDR, TT versus TC+CC, adjusted odds ratio of 0.90 (95% confidence interval, 0.68-1.19)) or clinical phenotypes (P-value40.05). The effects of the PTGDR and LTC4S polymorphisms on the enhancement of eosinophil counts were additive in the Korean children with asthma. In addition, the PTGDR polymorphism seems to be associated with the responsiveness to LTRA. Therefore, therapies that target the PTGDR may be useful for modulating the responsiveness to LTRA.
INTRODUCTION
Asthma is a complex disease that results from interactions among multiple genes and environmental factors. 1 The Th2 cytokine-driven inflammatory mechanisms have an important role in the pathophysiology of asthma. 2 Th2 cytokines, such as interleukin-4, interleukin-13 and interleukin-5, participate in the synthesis of immunoglobulin E (IgE), 3 and promote allergic eosinophilic inflammation and airway remodeling. 4 Asthma is often triggered by mast cells that are activated by an IgEmediated allergic challenge. 5 Activated mast cells produce a variety of chemical mediators including prostaglandin D2 (PGD2), which is the major cyclooxygenase metabolite of arachidonic acid, in response to allergen exposure. 6 PGD2 may contribute to pulmonary vasodilation, bronchoconstriction, and the recruitment of eosinophils, basophils and T-lymphocytes. [7] [8] [9] PGD2 exerts its biological actions through the PGD2 receptor (PTGDR), which is localized to chromosome 14q22.1 and has been associated with asthma. 10 The association between asthma and PTGDR function has been recently studied with a mouse model. PTGDR-knockout mice (PTGDR À/À ) show only marginal infiltration of eosinophils, reduced levels of Th2 cytokines and accumulation of lymphocytes in the lungs, and no development of bronchial hyperresponsiveness on ovalbumin challenge compared with wild-type controls. 8 These findings suggest that asthma could be inhibited when the PTGDR is absent. The existence of genetic variants in the promoter region of the PTGDR (À549, À441 and À197) have been reported for several ethnic groups. [11] [12] [13] [14] These three polymorphisms were not always related to asthma, but they may have a role in controlling PTGDR expression. Therefore, the PTGDR may serve as a therapeutic target for asthma.
Leukotriene C4 (LTC4) and PGD2 are converted from arachidonic acid by 5-lipoxygenase and cyclooxygenase, respectively. [15] [16] [17] However, the results of a recent study showed that PGD2 activated eosinophils and enhanced LTC4 synthesis in vivo. 18 Accumulating evidence suggests that the cysteinyl leukotrienes (cysLTs) are the primary mediators of exercise-induced bronchoconstriction (EIB), as demonstrated by the detection of cysLTs in the airways, 19 increased levels of urinary leukotriene E4 20 and increased levels of cysLTs in exhaled breath condensates, 21 and in induced sputum 22 from children with EIB. Therefore, we presume that the function of PGD2 may affect the response of the leukotriene receptor antagonist (LTRA), which inhibits the effect of leukotriene, although the PTGDR is not directly included in the LTRA pathway. The purpose of this study was to understand the relationship between the presence of polymorphisms in the promoter region of the genes for leukotriene C4 synthase (LTC4S) and PTGDR and the responsiveness to a LTRA.
MATERIALS AND METHODS Subjects
We collected DNA samples from subjects who came to asthma and allergy clinics and general pediatric clinics at the Asan Medical Center (270 normal children and 870 children with asthma). The normal controls had no history of asthma, other allergic diseases or airway hyperresponsiveness (PC 20 (concentration of methacholine that provoked a 20% fall in FEV 1 ) 416 mg ml À1 ). They had negative result of skin prick tests, normal total IgE values (p100 IU ml À1 ) and normal lung function tests. We enrolled all children with asthma who were diagnosed (i) by their physician and met the criteria set forth in the American Thoracic Society guidelines; (ii) on the basis of a history of dyspnea and wheezing during the previous 12 months; or (iii) as having a 412% FEV 1 after b 2 -agonist inhalation, a methacholine provocation test indicating airway hyperresponsiveness (PC 20 o16 mg ml À1 ) or both. The subjects who satisfied the American Thoracic Society guidelines and had negative result of skin prick tests and normal total IgE levels (p100 IU ml À1 ) defined non-atopic asthmatics.
The subjects with asthma who were included in the drug responsiveness analysis performed an exercise provocation test, from the middle of July to the beginning of November, with all measurements conducted between 1500 and 17 hours. The FEV 1 of this subjects decreased by at least 15% following the standardized exercise challenge. Subjects were excluded from the study if they had been treated in the previous 3 months with orally administered or inhaled corticosteroids, long-acting b 2 -agonists or a LTRA other than a short-acting b 2 -agonist, or if they had experienced an exacerbation in their asthma or a respiratory tract infection within the 4 weeks before entering the study.
This study was approved by the ethics committee of the Asan Medical Center Institutional Review Board, and written informed consent was obtained from the parents of all study participants.
Serum IgE and skin prick tests
Total serum IgE concentrations were measured by fluorescent enzyme immunoassay using the AutoCAP System (Phadia AB, Uppsala, Sweden). Skin prick tests were performed using a panel of 27 common Korean aeroallergens (Allergopharma, Reinbek, Germany). A test was considered 'positive' if the maximum wheal diameter was 3 mm.
LTRA drug responsiveness study design
In all, 100 subjects with asthma performed an exercise challenge test twice both before and after receiving their daily dose of montelukast (5 mg per day) for 8 weeks. The standardized exercise challenge consisted of 8 min of free running outdoors, as previously described. 23, 24 Subjects showing a X10% post-treatment improvement in the maximum percentage fall in FEV 1 were defined as 'responders' , and those subjects exhibiting o0% improvement (worsened values) in the maximum percentage fall in FEV 1 were defined as 'nonresponders' . Improvement (%) was calculated with the following formula: 100Â [(maximum percentage fall in FEV 1 before treatmentÀmaximum percentage fall in FEV 1 after treatment)/maximum percentage fall in FEV 1 before treatment].
Genotyping
DNA was isolated from blood samples from each subject using a G-DEX II kit (Intron, Seoul, Korea). PCR-restriction fragment length polymorphism was used to determine the polymorphisms. The primer pairs and annealing temperatures were as follows: 5¢-cgagttcttggccaccccagttcaaacaccagcacaa-3¢ and 5¢-ggagcaggccagtgaaga-3¢ and 57 1C for the PTGDR À441T/C (rs803010); 5¢-CCTCAGTTTCCTCGCCTATG-3¢ and 5¢-GGCCAAGAACTCGAAAGATG-3¢ and 56 1C for the PTGDR À549T/C (rs8004654); and 5¢-tacaacgactaaggc tggca-3¢ and 5¢-gctgtgtgtgaaggcgagc-3¢ and 581C for the LTC4S À444A/C (rs730012). The restriction enzymes were as follows: Mfe I (New England BioLabs, Beverly, MA, USA) digested the PTGDRÀ441T allele into 195 and 35 bp fragments, HpyAV (New England BioLabs) digested the PTGDR À549C allele into 125 and 74 bp fragment and Msp I (New England BioLabs) digested the LTC4S À444C allele into 388, 169 and 32 bp fragments. To confirm the accuracy of restriction fragment length polymorphism analysis, we randomly selected 20% of the subjects for DNA sequencing of each polymorphism. The observed genotype distributions of the PTGDR À441T/C, À549T/C and LTC4S À444A/C did not deviate significantly from the Hardy-Weinberg equilibrium (P¼0.377, P¼0.372 and P¼0.346, respectively).
Statistical analyses
The clinical parameters (for example, total IgE, PC 20 , total eosinophil count (TEC)) were converted into log 10 -based values in order to produce a normal distribution for the statistical analyses, and then the data were analyzed with Mann-Whitney U-tests. Subject demographic variables (for example, sex and age) were analyzed by multiple logistic regressions in order to determine whether or not the presence of particular alleles was disproportionate among the subjects. To analyze associations between the genotypes and asthma, we adopted a dominant model for the minor allele, assuming it was the risk allele and because relatively few individuals were homozygous for the risk alleles. An unconditional logistic regression analysis, adjusted for age and sex, was used to calculate the odds ratios, 95% confidence intervals and P-values. The relationship between clinical phenotype and genotype was tested using linear regression. The w 2 -tests were used to examine the relationship between responder or non-responder status and the LTC4S and PTGDR polymorphisms. All statistical analyses were performed using SPSS 18.0 for Windows (SPSS, Chicago, IL, USA), and P-values of p0.05 were considered statistically significant. And bootstrapping (1000 times) was carried out for significant association and combination between two polymorphisms.
RESULTS

Clinical characteristics
We administered montelukast daily to 100 of the subjects with asthma, for 8 weeks, and subsequently divided the subjects into two groups: responders and non-responders. There were 92 subjects included in this analysis and, of these, 69 subjects (75%) were responders (X10% improvement) and 23 subjects (25%) were non-responders (o0% improvement). The improvement of the 92 subjects was calculated by a numerical formula, and the percentages ranged from À113.1% to 95.0%. We compared the responders and non-responders in terms of their eosinophil fraction, log IgE levels, log PC 20 levels, baseline maximum percentage fall in FEV 1 after exercise and pulmonary function, and there were no differences between the two groups. Sex ratio seems that there might be a difference, however, it is not different statistically (P¼0.075 by w 2 -test). The responders and non-responders were randomly selected among 278, exercise-induced asthmatics who performed the exercise challenge test and who showed positive, EIB. However, as usually the severe EIB (+) subjects suggested severe asthmatic patients, LTRA treatment only may be used in mild asthmatics if their parents prefer it. Therefore, the maximum % fall in FEV 1 (%) differed in the subjects included in the LTRA study and in those who were excluded (Table 1) .
Relationship between LTRA responsiveness and frequency of LTC4S and PTGDR polymorphisms The PTGDR À549T/C and À441T/C polymorphisms were in almost complete linkage disequilibrium (D¢¼0.978), so we analyzed one among two polymorphisms. We chose a dominant model for the minor allele and analyzed the distributions of the LTC4S À444A/C and PTGDR À441T/C polymorphisms because the percentage of homozygous for the minor allele of the two polymorphisms was not 47.69%. The prevalence of the LTC4S À444A/C polymorphism did not differ between the responders and non-responders (P¼0.702), but there was a higher number of non-responders that were heterozygous or homozygous for the C allele of the PTGDR À441T/C polymorphism (P¼0.038, Table 2 ).
We investigated how combinations of the LTC4S À444A/C and PTGDR À441T/C polymorphisms influenced the responsiveness of the subjects to a LTRA. The possible polymorphism combinations were determined according to the dominant model, as listed in Table 3 , afterward group II, III and IV compared with group I. A significant difference in combination was not observed among each group (Table 3) .
Frequency of LTC4S and PTGDR polymorphisms in children with asthma We analyzed the frequency of the LTC4S À444A/C and PTGDR À441T/C polymorphisms among the normal children and the children with asthma, atopic asthma or non-atopic asthma. The frequency of the minor allele of the LTC4S À444A/C polymorphism was 0.18 for the normal children and 0.17 for the children with asthma. The frequency of the minor allele of the PTGDR À441T/C polymorphism was 0.26 for the normal children and 0.25 for the children with asthma. The frequency of the minor allele for the children with asthma was identical to the frequency for the children with atopic asthma. The LTC4S À444A/C and PTGDR À441T/C polymorphisms were not significantly associated with children with asthma, atopic asthma or non-atopic asthma compared with normal children in an additive, recessive and dominant model ( Table 4) .
Relationship of eosinophils to the LTC4S À444A/C and the PTGDR À441T/C polymorphisms Because leukotriene is secreted from eosinophils, a high TEC is one of the distinguishing features of asthma, and because PGD2 may contribute to the recruitment of eosinophils, we investigated the relationship between the number of eosinophils and the LTC4S À444A/C and PTGDR À441T/C polymorphisms in children with asthma or atopic asthma. Interestingly, as the number of minor alleles of these two polymorphisms increased, the log TEC increased in the children with atopic asthma (P¼0.03). There was a tendency for the log TEC to increase in the children with asthma, but the effect was not statistically significant ( Figure 1) . We compared the difference in eosinophil counts in non-atopic asthmatics and atopic asthmatics in each combination group. According to the comparative results, log TEC was higher in atopic asthmatics than in non-atopic asthmatics (Supplementary Table 1 ).
DISCUSSION
In this study, we have shown a significant effect of the presence of the PTGDR À441T/C polymorphism on responsiveness to a LTRA during an exercise challenge model of bronchial responsiveness in children with asthma. In addition, we have found a correlation between TEC increment and the combined presence of the PTGDR À441T/C and LTC4S À444A/C polymorphisms in children with atopic asthma. However, the presence of these two polymorphisms was not associated with asthma susceptibility in Korean children with asthma. The PTGDR is located at chromosome 14q22.1 and is the receptor for PGD2 that may contribute to the asthma phenotype, which is characterized by pulmonary vasodilation, bronchoconstriction and recruitment of eosinophils. [7] [8] [9] The effects of the PTGDR on asthma were shown with a mouse study; the asthmatic symptoms of PTGDR À/À mice were improved compare with wild-type mice. 8 In addition, PGD2 15 and LTC4 16, 17 are both derived from arachidonic acid. However, the relationship between the PTGDR and responsiveness to a LTRA has not been investigated. We considered three single-nucleotide polymorphisms (SNPs; À197T/C, À441T/C and À549T/C) in the PTGDR gene. These three SNPs have been investigated in many previous studies. The À441T/C polymorphism was associated with asthma development in the white population 11 but not in the Mexican population. 12 The À549T/C and À197T/C polymorphisms are associated with asthma development in the black 11 and Caucasian populations 13 , respectively. However, three SNPs were not significant in the Chinese population, as noted in our results. 14 These findings may be caused by the difference in allele frequency in a particular ethnic group. In fact, we confirmed the difference of 0.2 to 0.4 in Asians and CEPH (Utah residents with ancestry from northern and western Europe) according to the HapMap data. Although it is not a data from Asian, a minor allele frequency of À197T/C polymorphism is very low (about 10%) in European. And two SNPs (À441T/C and À549T/C) were in strong linkage disequilibrium. Therefore, we examined the relationship between the PTGDR À441T/C polymorphism and responsiveness to LTRA, and found that subjects with heterozygous or homozygous C alleles were more likely to be non-responders. In addition, we analyzed the effect of the combined presence of the PTGDR À441T/C and LTC4S À444A/C polymorphisms because LTRA improves the asthmatic symptoms of Figure 1 This figure shows the combined effect of the leukotriene C4 synthase (LTC4S) À444A/C and the prostaglandin D2 receptor (PTGDR) À441T/C polymorphisms on the log total eosinophil count (TEC) in children with asthma or atopic asthma. Groups with the LTC4S À444A/C and PTGDR À441T/C polymorphisms were combined. The data are presented as the mean±s.e.m. and were analyzed by linear regression. *P¼0.03 in atopic asthma.
subjects by impeding the function of leukotriene. The PGD2 recruits eosinophils 8 and induces the synthesis of LTC4 by stimulating the eosinophils. 18 Also the LTC4S À444A/C polymorphism was associated with leukotriene production and asthma in several independent studies. 25, 26 Although the LTC4S À444A/C polymorphism was always not associated with asthma susceptibility or severity, 26, 27 this polymorphism is universally most common SNP. Therefore, we investigated a combined effect of the PTGDR (À441T/C) and LTC4S (À444A/C) polymorphisms in EIB model after treatment with LTRA. However, there were no significant differences between the responders and non-responders of this study when we analyzed the combined frequencies of the PTGDR and LTC4S polymorphisms. PGD2 may contribute to the recruitment of eosinophils, 8 and LTC4, a potent biomarker produced by eosinophils, 28 has been shown to be a strong mediator of bronchoconstriction in EIB. 29 We previously reported that children with asthma who also experienced EIB had significantly higher TEC. 30 In addition, the results of several studies suggest that the presence and severity of EIB is significantly associated with the number of eosinophils measured from the blood and sputum of subjects with asthma. [31] [32] [33] [34] Therefore, we hypothesized that eosinophils contribute to the mechanisms underlying EIB and the therapeutic effects of LTRA therapy, and then we investigated the effects of polymorphism combinations on LTRA drug responsiveness and on TEC in children with asthma. Interestingly, we found that the presence of the PTGDR À441C and LTC4S À444C alleles appeared to be associated with increased TEC in children with asthma, especially children with atopic asthma. In Supplementary Table 1, the reason for the higher TEC in atopic asthmatics than in non-atopic asthmatics, may be atopy and is not a combination of two polymorphisms. In fact, we confirmed that log TEC increases if log IgE increased in our asthmatics (Supplementary Figure 1) . We additionally analyzed a change of eosinophil count according to combination of the two SNPs in responder (69 subjects), non-responder (23 subjects) and total 100 subjects of LTRA, respectively. However, there were not increasing trend of eosinophil counts (data not shown). Therefore, the association between responsiveness to LTRA in 100 subjects and increased number of eosinophils in atopic asthmatics may be not direct because of two different groups of subjects. However, individuals with C allele of the PTGDR have high eosinophil counts, the PTGDR was expressed on eosinophil and leukotrienes were secreted from eosinophils. We also analyzed the association between TEC and each polymorphism. Children who were heterozygous or homozygous for the minor allele of the PTGDR À441T/C or LTC4S À444A/C polymorphisms tended to have higher TEC than children who were homozygous for the common allele; however, the effect was not statistically significant (data not shown). Altogether, we thought that increment of eosinophil count in atopic asthmatics is result worth considering certainly. Increased levels of cysLTs have been detected in airways, 19 exhaled breath condensates 21 and induced sputum, 22 and bronchial hyperresponsiveness has been induced by administration of cysLTs. 35 PTGDR expression was increased by the region including À441C allele 14 and increased expression of the PTGDR augmented the ability of PGD2 to recruit eosinophils and stimulate them to synthesize LTC4. 18 According to our data, the combined effects of the LTC4S À444C and PTGDR À441C alleles may have an additive effect on increasing TEC. Ultimately, higher levels of LTC4 disrupt LTRA responsiveness in children with asthma ( Figure 2) .
A weakness of our study is that there is not a clear cutoff value that distinguishes responders from non-responders. However, to our knowledge, there are no published research findings that address this issue. The classification system used in this study enabled us to include 92 subjects, which was sufficient to analyze drug responsiveness. Second, other genes may be connected on LTRA responsiveness, for instance, cysLT 1 , which is receptor of leukotriene and interleukin-5, which is cytokine that acts as a growth and differentiation factor for eosinophils may be associated with LTRA responsiveness. However, we only investigated two polymorphisms in two genes. In the future, more studies are needed to validate these results with more genes in The pathway of enhanced leukotrienes production by PGD2 in eosinophils, which is affected by PTGDR and LTC4S polymorphisms. Increased expression of PTGDR by the PTGDR À441C allele augments the function of PGD2. Also increased function of PGD2 recruits more eosinophils and induces the synthesis of leukotriene by stimulating the eosinophils. Increased eosinophils by the PGD2 via increased PTGDR by polymorphism and an additive effect of the PTGDR À441C and the LTC4S À444C allele produce the leukotriene more a lot. In the event, increased concentrations of the leukotriene may inhibit the LTRA responsiveness, which is affected by exercise-induced bronchoconstriction.
larger population. Third, EIB test is more accurate indoor than outdoor. We conducted free running at outdoor to provoke maximal stimulation of EIB and calculated temperature (19±581C) and humidity (57 ± 12%) during day of testing. 30 We performed all of these study population using the same maneuver, although there might have been limited differences in the climatic conditions compared with the standard treadmill test. The last, two SNPs in this study were associated by genotype and combination at nominal level of significance. Despite these limitations, our data may use for drug responsiveness because we compared result of medication before and after in same subjects, also the current finding of association study on LTRA responsiveness helps to possible personalized medication. In summary, we report for the first time that the PTGDR À441C allele seems to be associated with LTRA responsiveness and that increases in TEC are associated with the LTC4S À444C and PTGDR À441C allele. Individual polymorphisms may have a small influence in complex diseases such as asthma. However, a combination of polymorphisms in entire pathway gives help to understand complex disease. Our results suggest that there is variability in the response to LTRA that is related to genotype, and this information may help identify more selective therapeutic strategies.
